BRPI0909762A2 - Formas cristalinas e duas formas solvatas de sais do ácido láctico de 4-amino-5-flúor-3-[5-(4- metilpiperazin-1-il)-1h-benzimidazol-2-il[quinolin-2- (1h)-ona - Google Patents

Formas cristalinas e duas formas solvatas de sais do ácido láctico de 4-amino-5-flúor-3-[5-(4- metilpiperazin-1-il)-1h-benzimidazol-2-il[quinolin-2- (1h)-ona

Info

Publication number
BRPI0909762A2
BRPI0909762A2 BRPI0909762A BRPI0909762A BRPI0909762A2 BR PI0909762 A2 BRPI0909762 A2 BR PI0909762A2 BR PI0909762 A BRPI0909762 A BR PI0909762A BR PI0909762 A BRPI0909762 A BR PI0909762A BR PI0909762 A2 BRPI0909762 A2 BR PI0909762A2
Authority
BR
Brazil
Prior art keywords
forms
ona
benzimidazol
methylpiperazin
quinolin
Prior art date
Application number
BRPI0909762A
Other languages
English (en)
Portuguese (pt)
Inventor
Schreiner Andreas
Giron Danielle
Stowasser Frank
Polasek Johanne
Piechon Philippe
Hammerschmidt Walter
Original Assignee
Novatis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909762(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novatis Ag filed Critical Novatis Ag
Publication of BRPI0909762A2 publication Critical patent/BRPI0909762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0909762A 2008-03-19 2009-03-18 Formas cristalinas e duas formas solvatas de sais do ácido láctico de 4-amino-5-flúor-3-[5-(4- metilpiperazin-1-il)-1h-benzimidazol-2-il[quinolin-2- (1h)-ona BRPI0909762A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
BRPI0909762A2 true BRPI0909762A2 (pt) 2018-04-03

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909762A BRPI0909762A2 (pt) 2008-03-19 2009-03-18 Formas cristalinas e duas formas solvatas de sais do ácido láctico de 4-amino-5-flúor-3-[5-(4- metilpiperazin-1-il)-1h-benzimidazol-2-il[quinolin-2- (1h)-ona

Country Status (24)

Country Link
US (1) US8563556B2 (enExample)
EP (1) EP2257544B1 (enExample)
JP (1) JP2011515370A (enExample)
KR (1) KR20100137517A (enExample)
CN (1) CN101970425B (enExample)
AR (1) AR070924A1 (enExample)
AU (1) AU2009227003B2 (enExample)
BR (1) BRPI0909762A2 (enExample)
CA (1) CA2718076A1 (enExample)
CL (1) CL2009000651A1 (enExample)
CO (1) CO6321253A2 (enExample)
EC (1) ECSP10010555A (enExample)
IL (1) IL208020A0 (enExample)
MA (1) MA32230B1 (enExample)
MX (1) MX2010010152A (enExample)
MY (1) MY150554A (enExample)
NZ (2) NZ600887A (enExample)
PE (1) PE20091628A1 (enExample)
PH (2) PH12012502569A1 (enExample)
RU (1) RU2497820C2 (enExample)
SG (1) SG188919A1 (enExample)
TW (1) TWI426072B (enExample)
WO (1) WO2009115562A2 (enExample)
ZA (1) ZA201006263B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2011128405A1 (en) 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds
PL2558095T3 (pl) 2010-04-16 2019-06-28 Novartis Ag Związek organiczny, przeznaczony do stosowania w leczeniu raka wątroby
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
AU2012229107A1 (en) 2011-03-17 2013-09-19 Novartis Ag FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
KR20140062485A (ko) 2011-09-15 2014-05-23 노파르티스 아게 중등도 간 손상 환자의 암 치료에 있어서 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온의 용도
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2015505562A (ja) 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309996T1 (de) * 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
JP4890255B2 (ja) * 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
RU2377988C2 (ru) * 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
SG173317A1 (en) * 2005-01-27 2011-08-29 Novartis Vaccines & Diagnostic Treatment of metastasized tumors
AU2006249847B2 (en) * 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
NZ567550A (en) 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme

Also Published As

Publication number Publication date
AR070924A1 (es) 2010-05-12
US8563556B2 (en) 2013-10-22
EP2257544A2 (en) 2010-12-08
ZA201006263B (en) 2011-05-25
RU2010142396A (ru) 2012-04-27
CN101970425B (zh) 2014-04-16
MA32230B1 (fr) 2011-04-01
RU2497820C2 (ru) 2013-11-10
WO2009115562A2 (en) 2009-09-24
CL2009000651A1 (es) 2010-07-19
IL208020A0 (en) 2010-12-30
PH12012502568A1 (en) 2014-10-27
AU2009227003B2 (en) 2013-03-14
AU2009227003A1 (en) 2009-09-24
HK1147492A1 (en) 2011-08-12
CN101970425A (zh) 2011-02-09
KR20100137517A (ko) 2010-12-30
TWI426072B (zh) 2014-02-11
CO6321253A2 (es) 2011-09-20
MX2010010152A (es) 2010-10-25
ECSP10010555A (es) 2010-11-30
PH12012502569A1 (en) 2015-09-21
WO2009115562A3 (en) 2009-11-26
EP2257544B1 (en) 2014-12-03
CA2718076A1 (en) 2009-09-24
JP2011515370A (ja) 2011-05-19
US20110021536A1 (en) 2011-01-27
TW201000463A (en) 2010-01-01
SG188919A1 (en) 2013-04-30
NZ587829A (en) 2012-08-31
NZ600887A (en) 2013-10-25
MY150554A (en) 2014-01-30
PE20091628A1 (es) 2009-11-19

Similar Documents

Publication Publication Date Title
BRPI0909762A2 (pt) Formas cristalinas e duas formas solvatas de sais do ácido láctico de 4-amino-5-flúor-3-[5-(4- metilpiperazin-1-il)-1h-benzimidazol-2-il[quinolin-2- (1h)-ona
BRPI0915714A2 (pt) forma cristalina de posaconazol
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0811361A2 (pt) Suspenção concentrada de tiodiazol-zinco e seu método de preparação
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
DK3290530T3 (da) Konservering af cellefrie nukleinsyrer
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
DK2424972T3 (da) Kryobeskyttende midler til frysetørring af mælkesyrebakterier
DK2386171T3 (da) Tilpasning af overgivelsesparametre
DK2262793T3 (da) Krystallinske former af nilotinib-hci
PT2730564T (pt) Aminas heterocíclicas e suas utilizações
BRPI1015409A2 (pt) composição aquosa de flureto de polivinilideno
SMT201900049T1 (it) Composti eterociclici e loro utilizzi
EP2232781A4 (en) DEVELOPMENT OF ETHERNET NETWORKS
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
BRPI0922248A2 (pt) eletrodo e método de produção do mesmo
HRP20171612T2 (hr) Umrežujuće spojnice i njihova upotreba
DK2730646T4 (da) Tørring af mælkesyrebakterier og nye sammensætninger
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
BRPI0920183A2 (pt) derivados de fenetilamida e seus analogos heterociclicos
IL208979B (en) Humanized antibodies against human interferon-alpha
DK2243711T3 (da) Fremstilling af båndprodukter med diagnostiske hjælpemidler
EP2457933A4 (en) LATEX AND LABELING COMPOSITION THEREOF
DK2194784T3 (da) Kombinationer af aktive midler med insekticidale og acaricidale egenskaber
BR112012001253A2 (pt) Confeito com múltiplas regiões e método de fabricação do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]